Skip to content

PEDEVCO PED Proceeds From Issuance Of Convertible Preferred Stock

Proceeds From Issuance Of Convertible Preferred Stock at other companies

KKR & Co. logo
KKR & Co.KKR
$0-100%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$26.55M
QuantumScape Corporation
 logo
QuantumScape Corporation QS
$44.12M
Maze Therapeutics, Inc. Common Stock logo
Maze Therapeutics, Inc. Common StockMAZE
$17.7M
Evolution Metals & Technologies Corp.
 logo
Evolution Metals & Technologies Corp. EMAT
$5.55M
Patriot National Bancorp logo
Patriot National BancorpPNBK
$0-100%

Other financials

Income statement

See full
Revenue$40.2M+360%
Operating income$6.7M+4,369%
Net income-$25.6M-18,405%
EPS (diluted)-$3.28-11,033%

Balance sheet

See full
Cash & equivalents$7.7M-26.0%
Total debt$170.0K-16.3%
Total equity$182.2M+56.8%
Total assets$370.1M+154%

Cash flow

See full
Operating cash flow$10.5M+77.7%
CapEx--100%
Free cash flow$2.7M-14.6%

Valuation

See full
Market cap$179.04M+198%
Enterprise value$171.5M+230%
P/S2.6×+0.9×

Profitability

See full
Operating margin-1.9%
Net margin-52.9%-81.9pp
FCF margin29.2%-2.7pp

Returns & leverage

See full
Return on equity-24.2%-35.0pp
Debt / equity0.0×
Current ratio0.7×-0.7×

Where this comes from

Reported directly by PEDEVCO in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock.

The official record: PEDEVCO’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about PEDEVCO's proceeds from issuance of convertible preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PEDEVCO's proceeds from issuance of convertible preferred stock?
PEDEVCO (PED) reported proceeds from issuance of convertible preferred stock of $8.75M in Q4 2025.